Related Experiment Video

Updated: Aug 17, 2026

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

14.9K

Roles and regulatory mechanisms of KIN17 in cancers (Review)

Xueran Huang1, Zichang Dai2, Qiuyan Li1,3

  • 1Medical Laboratory, Affiliated Hospital of Guangdong Medical University, Zhanjiang, Guangdong 524000, P.R. China.

Oncology Letters
|March 13, 2023
PubMed

Insights

The DNA and RNA binding protein KIN17 is highly expressed in human cancers, promoting tumor growth and poor prognosis. Reducing KIN17 enhances chemotherapy sensitivity, suggesting its potential as a cancer biomarker and therapeutic target.

Area of Science:

  • Molecular Biology
  • Oncology
  • Biochemistry

Background:

  • KIN17 is a DNA and RNA binding protein implicated in essential cellular processes.
  • High expression of KIN17 is observed across various human cancers.
  • KIN17 plays a role in cell proliferation, migration, invasion, and cell cycle regulation.

Purpose of the Study:

  • To investigate the role of KIN17 in tumorigenesis and cancer development.
  • To evaluate KIN17 as a potential diagnostic and prognostic biomarker.
  • To explore KIN17 as a therapeutic target in cancer treatment.

Main Methods:

  • Immunohistochemical analysis to compare KIN17 expression in cancer and adjacent tissues.
  • Kaplan-Meier survival analysis and multivariate Cox regression analysis.
  • Assessment of KIN17 knockdown effects on tumor cell sensitivity to chemotherapeutic agents.

Main Results:

  • KIN17 is aberrantly overexpressed in diverse tumor tissues compared to normal tissues.
  • High KIN17 expression correlates with poor prognosis in cancer patients.
  • Knockdown of KIN17 increases the sensitivity of tumor cells to chemotherapy.

Conclusions:

  • KIN17 is a key driver in tumorigenesis and cancer progression.
  • KIN17 serves as a potential diagnostic and prognostic biomarker for various cancers.
  • Targeting KIN17 may offer a novel therapeutic strategy for cancer treatment.
Keywords:
KIN17cancerchemoresistanceepigenetic modificationinvasionmethylationmigrationtranscription regulator

More Related Videos

Impedance-based Real-time Measurement of Cancer Cell Migration and Invasion09:23

Impedance-based Real-time Measurement of Cancer Cell Migration and Invasion

Published on: April 2, 2020

6.5K
Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants07:39

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

200

Related Concept Videos

Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Mechanisms of Retrovirus-induced Cancers01:51

Mechanisms of Retrovirus-induced Cancers

Retroviruses are RNA viruses that have been shown to cause cancers in diverse species, including chickens, mice, cats, and monkeys. The RNA genomes of these viruses are first reverse-transcribed into single and then double-stranded DNA (dsDNA) copies. This dsDNA called proviral DNA then integrates into the host genome. Subsequently, the host cell transcribes the proviral DNA in concert with the chromosomal DNA. This leads to the production of viral RNA and proteins that assemble at the host...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...